LS patients are more likely to die as a result of UTUC than CRC [36], and MSH2-variant carriers are at particular risk, with a >20% chance of developing a UTUC by the age of 75 [2]. Here, MSH2 is linked to renal pelvis/ureter urothelial carcinoma.